AbbVie, Obesity

AbbVie Joins Obesity Treatment Market With Up to $2.2B Licensing Deal
Key Takeaways AbbVie agreed to license a weight-loss drug in development from Danish biotech firm Gubra.AbbVie said it will pay up to about $2.2 billion for the drug GUBamy, which is currently in a Phase 1 clinical trial.
AbbVie gets into obesity with $350M deal for once-weekly shot
A licensing deal with Denmark’s Gubra gives the immunology giant control of an experimental therapy that could compete with drugs from Novo Nordisk, Eli Lilly and Zealand.
AbbVie Enters The Obesity Arena. Why It's Paying Up To $2.23 Billion.
AbbVie inked a licensing deal Monday worth up to $2.23 billion for an amylin-targeting obesity treatment from Denmark-based Gubra A/S.
Abbvie enters $2.2B deal for Gubra’s amylin obesity drug
Abbvie Inc. is buying into the obesity fray in a potential $1.875 billion development and commercialization agreement with Danish peptide drug discovery specialist Gubra A/S. In addition, there will be a $350 million up-front payment as Abbvie takes over the reins of GUB-014295 (referred to as Gubamy),
AbbVie steps into the obesity drug race, licensing medicine from Danish firm
The obesity medicine field has gained a new entrant, with AbbVie licensing an experimental drug from a Danish company.
AbbVie and Gubra ink license agreement to develop an amylin analog for the treatment of obesity
North Chicago, Illinois Tuesday, March 4, 2025, 10:00 Hrs [IST]
AbbVie, Gubra in Obesity-Drug License Pact Potentially Worth More Than $2 Billion
AbbVie is jumping into the burgeoning obesity field, striking a license agreement with Gubra that is potentially worth more than $2 billion to the Danish drug-discovery and contract-research-services company.
AbbVie, Gubra announce license agreement to develop GUB014295
AbbVie (ABBV) and Gubra announced a license agreement to develop GUB014295, a long-acting amylin analog for the treatment of obesity. Under the
AbbVie Becomes Another Big Pharma To Enter Obesity Treatment Race
AbbVie partners with Gubra in a $2.2 billion deal to develop GUB014295, an amylin analog for obesity. The move marks AbbVie's entry into the competitive weight-loss market.
AbbVie Enters Obesity Market Through Licensing Deal With Denmark's Gubra
AbbVie (ABBV) on Monday said it struck a licensing deal with Danish biotechnology company Gubra to develop a potential candidate for obesity treatment. AbbVie will be responsible for the global development and commercialization activities of GUB014295,
ABBV Enters Obesity Bandwagon, Inks $2.2B Licensing Deal for Amylin Drug
AbbVie ABBV announced that it has entered into a licensing agreement with Denmark-based biotech Gubra for the latter’s experimental obesity drug, GUB014295. This marks the American drugmaker’s foray into the lucrative obesity market.
Pharm Exec16h
AbbVie, Gubra Strike Deal to Develop Novel Weight Loss Treatment
Under terms of the deal, Gubra will receive an initial $350 million payment and could earn up to $1.875 billion more in ...
FierceBiotech23h
AbbVie pays Gubra $350M to make late play for obesity space
AbbVie is paying $350 million to join the obesity race. The outlay, plus up to $1.875 billion in milestones, has landed the ...
AbbVie, Reddit, Allegro MicroSystems: Market Minute
Yahoo Finance host Josh Lipton tracks the day's biggest stocks in this Market Minute. AbbVie (ABBV) announced a licensing ...